Gildea, L.; Ayariga, J.; Villafane, R. P22 Phage Shows Promising Antibacterial Activity Under Pathophysiological Conditions. Preprints2021, 2021110248. https://doi.org/10.20944/preprints202111.0248.v1
APA Style
Gildea, L., Ayariga, J., & Villafane, R. (2021). P22 Phage Shows Promising Antibacterial Activity Under Pathophysiological Conditions<strong> </strong>. Preprints. https://doi.org/10.20944/preprints202111.0248.v1
Chicago/Turabian Style
Gildea, L., Joseph Ayariga and Robert Villafane. 2021 "P22 Phage Shows Promising Antibacterial Activity Under Pathophysiological Conditions<strong> </strong>" Preprints. https://doi.org/10.20944/preprints202111.0248.v1
Abstract
The prevalence of multidrug resistant bacterial diseases is a major global health risk. Multidrug resistant bacterial diseases are prevalent, and the need for novel methods of treatment is essential to the preservation of public health. Annually foodborne pathogens cause 1.35 million infections and 26,500 hospitalizations in the United States alone. Foodborne pathogens such as Salmonella spp. are a major threat to public health. Bacteriophages offer a unique method for the treatment of these multidrug resistant bacteria. We studied the infection dynamics of a potential mono-phage therapy of Salmonella typhimurium under various pathophysiological conditions. Furthermore, we determined the resistance dynamics of Salmonella typhimurium against P22 phage treatment. We also determined synergy with antibiotics such as ampicillin and kanamycin. This research helps to further define and show the versatility of bacteriophages as potential novel treatment methods.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
